Ana shirin shiga wani sabon babi a harkar rage kiba, domin masana’antu da ‘yan kasuwa na ganin nan gaba magungunan GLP-1 za su zama kamar biyan kuɗin wata-wata na “subscription”, inda ake sarrafa shan kwaya ta wayar hannu, tare da samun wadannan magunguna cikin sauƙi kamar sayen takalman wasanni. Kamfanonin Lilly da Novo Nordisk suna shirin ƙaddamar da pills maimakon allurai kaɗai, tare da dogaro da telehealth da biyan kuɗi kai tsaye domin isa ga miliyoyin Amurkawa.
Rahoton Reuters ya nuna cewa masana harkar lafiya, kamfanonin magunguna, masu saka jari da kamfanonin telehealth suna ganin kasuwar GLP-1 za ta koma kasuwar mabukata kai tsaye, inda amfani da manhajojin lafiya ke zama na yau da kullum. Manhajoji kamar Noom da Ro suna haɗa shan magani da ƙarfafa salon rayuwa – lafiya, kuzari, kyakkyawan jiki, kwanciyar hankali har ma da alaƙar aure.
Sabbin kwayoyin GLP-1 za su ba da damar:
Gujewa allura ga masu tsoron allurai
Sarrafa ƙananan ƙwayoyi ko shan magani na lokuta na musamman
Shiryawa don “holiday season” ko lokacin hutu
Sauƙin samun magani ta biyan kuɗi kai tsaye
Sai dai masana lafiya na gargadi kan hatsarin rage kulawar likita, kasancewar magungunan na iya haifar da matsalolin hanji, pancreatitis, damuwa da wasu illolin dogon lokaci da ba a tabbatar ba. Duk da haka masana’antu na ganin akwai kasuwar miliyoyin mutane, yayin da kamfanoni ke tura tallace-tallace ga TikTok, Reddit da sauran shafukan sada zumunta tare da tallace-tallacen taurari.
